NCT00833833 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 113
- group Id
- BG005
- value
- 108
- group Id
- BG006
- value
- 259
- units
- Participants
- groups
- description
- Pomalidomide 2 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.
- id
- BG000
- title
- Phase 1: 2 mg Pomalidomide
- description
- Pomalidomide 3 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.
- id
- BG001
- title
- Phase 1: 3 mg Pomalidomide
- description
- Pomalidomide 4 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.
- id
- BG002
- title
- Phase 1: 4 mg Pomalidomide
- description
- Pomalidomide 5 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.
- id
- BG003
- title
- Phase 1: 5 mg Pomalidomide
- description
- Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (either 40mg or 20 mg) on days 1, 8, 15, and 22 of each 28-day cycle.
- id
- BG004
- title
- Phase 2: Pomalidomide + Dexamethasone
- description
- 4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone at the starting dose in addition to their current dose of pomalidomide, or to discontinue treatment.
- id
- BG005
- title
- Phase 2: Pomalidomide
- description
- Total of all reporting groups
- id
- BG006
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.83
- value
- 64.7
- group Id
- BG001
- spread
- 6.63
- value
- 70.4
- group Id
- BG002
- spread
- 8.98
- value
- 67.5
- group Id
- BG003
- spread
- 14.06
- value
- 61.3
- group Id
- BG004
- spread
- 9.24
- value
- 64.4
- group Id
- BG005
- spread
- 10.35
- value
- 62.9
- group Id
- BG006
- spread
- 9.86
- value
- 64.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 99
- group Id
- BG005
- value
- 95
- group Id
- BG006
- value
- 226
- title
- <=75 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 14
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 33
- title
- >75 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 51
- group Id
- BG005
- value
- 51
- group Id
- BG006
- value
- 122
- title
- Female
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 62
- group Id
- BG005
- value
- 57
- group Id
- BG006
- value
- 137
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 7
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 17
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 34
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 92
- group Id
- BG005
- value
- 86
- group Id
- BG006
- value
- 213
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 5
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 53
- group Id
- BG005
- value
- 44
- group Id
- BG006
- value
- 110
- title
- Normal
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 56
- group Id
- BG005
- value
- 59
- group Id
- BG006
- value
- 140
- title
- Abnormal, not clinically significant
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- title
- Abnormal, clinically significant
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 8
- title
- Missing
- param Type
- NUMBER
- title
- Baseline Electrocardiogram Findings
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 32
- group Id
- BG005
- value
- 24
- group Id
- BG006
- value
- 62
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 68
- group Id
- BG005
- value
- 71
- group Id
- BG006
- value
- 163
- title
- 1
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 32
- title
- 2
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 2
- title
- 3
- description
- The ECOG scale is as follows: Grade 0: Fully active, able to carry on all pre-disease activities without restriction; Grade 1: Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; Grade 2: Ambulatory and capable of all self-care but unable to work. Up and about more than 50% of waking hours; Grade 3: Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4: Completely disabled. Cannot carry on any self-care. Confined to bed or chair.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group Performance Status
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 23
- title
- Stage I
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 29
- group Id
- BG005
- value
- 29
- group Id
- BG006
- value
- 64
- title
- Stage II
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 76
- group Id
- BG005
- value
- 71
- group Id
- BG006
- value
- 172
- title
- Stage III
- description
- Multiple myeloma has three stages, which are known as stage I, stage II and stage III. Staging in myeloma is done on the basis of the value of serum albumin and beta-2 microglobulin level. Stage I has the best prognosis and stage III the worst prognosis.
- param Type
- NUMBER
- title
- Baseline Multiple Myeloma Stage
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 113
- group Id
- BG005
- value
- 108
- group Id
- BG006
- value
- 259
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- title
- No
- param Type
- NUMBER
- title
- Prior Anti-Myeloma Therapies
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 76
- group Id
- BG005
- value
- 72
- group Id
- BG006
- value
- 178
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 37
- group Id
- BG005
- value
- 36
- group Id
- BG006
- value
- 81
- title
- No
- param Type
- NUMBER
- title
- Prior Thalidomide Exposure
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 84
- group Id
- BG005
- value
- 82
- group Id
- BG006
- value
- 191
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 29
- group Id
- BG005
- value
- 26
- group Id
- BG006
- value
- 68
- title
- No
- param Type
- NUMBER
- title
- Prior Stem Cell Transplant
- unit Of Measure
- participants
- population Description
- Intent to treat population from both phases
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 113
- group Id
- BG005
- value
- 108
- group Id
- BG006
- value
- 259
- units
- Participants
- groups
- description
- Pomalidomide 2 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.
- id
- BG000
- title
- Phase 1: 2 mg Pomalidomide
- description
- Pomalidomide 3 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.
- id
- BG001
- title
- Phase 1: 3 mg Pomalidomide
- description
- Pomalidomide 4 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.
- id
- BG002
- title
- Phase 1: 4 mg Pomalidomide
- description
- Pomalidomide 5 mg daily on days 1-21 of each 28-day cycle. Upon PD, participants had the option of discontinuing treatment or adding dexamethasone.
- id
- BG003
- title
- Phase 1: 5 mg Pomalidomide
- description
- Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (either 40mg or 20 mg) on days 1, 8, 15, and 22 of each 28-day cycle.
- id
- BG004
- title
- Phase 2: Pomalidomide + Dexamethasone
- description
- 4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone at the starting dose in addition to their current dose of pomalidomide, or to discontinue treatment.
- id
- BG005
- title
- Phase 2: Pomalidomide
- description
- Total of all reporting groups
- id
- BG006
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.83
- value
- 64.7
- group Id
- BG001
- spread
- 6.63
- value
- 70.4
- group Id
- BG002
- spread
- 8.98
- value
- 67.5
- group Id
- BG003
- spread
- 14.06
- value
- 61.3
- group Id
- BG004
- spread
- 9.24
- value
- 64.4
- group Id
- BG005
- spread
- 10.35
- value
- 62.9
- group Id
- BG006
- spread
- 9.86
- value
- 64.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 99
- group Id
- BG005
- value
- 95
- group Id
- BG006
- value
- 226
- title
- <=75 years
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 14
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 33
- title
- >75 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 51
- group Id
- BG005
- value
- 51
- group Id
- BG006
- value
- 122
- title
- Female
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 62
- group Id
- BG005
- value
- 57
- group Id
- BG006
- value
- 137
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 7
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 17
- group Id
- BG005
- value
- 16
- group Id
- BG006
- value
- 34
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 92
- group Id
- BG005
- value
- 86
- group Id
- BG006
- value
- 213
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 5
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 53
- group Id
- BG005
- value
- 44
- group Id
- BG006
- value
- 110
- title
- Normal
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 56
- group Id
- BG005
- value
- 59
- group Id
- BG006
- value
- 140
- title
- Abnormal, not clinically significant
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- title
- Abnormal, clinically significant
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 8
- title
- Missing
- param Type
- NUMBER
- title
- Baseline Electrocardiogram Findings
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 32
- group Id
- BG005
- value
- 24
- group Id
- BG006
- value
- 62
- title
- 0
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 68
- group Id
- BG005
- value
- 71
- group Id
- BG006
- value
- 163
- title
- 1
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 32
- title
- 2
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 2
- title
- 3
- description
- The ECOG scale is as follows: Grade 0: Fully active, able to carry on all pre-disease activities without restriction; Grade 1: Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; Grade 2: Ambulatory and capable of all self-care but unable to work. Up and about more than 50% of waking hours; Grade 3: Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4: Completely disabled. Cannot carry on any self-care. Confined to bed or chair.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group Performance Status
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 23
- title
- Stage I
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 29
- group Id
- BG005
- value
- 29
- group Id
- BG006
- value
- 64
- title
- Stage II
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 76
- group Id
- BG005
- value
- 71
- group Id
- BG006
- value
- 172
- title
- Stage III
- description
- Multiple myeloma has three stages, which are known as stage I, stage II and stage III. Staging in myeloma is done on the basis of the value of serum albumin and beta-2 microglobulin level. Stage I has the best prognosis and stage III the worst prognosis.
- param Type
- NUMBER
- title
- Baseline Multiple Myeloma Stage
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 113
- group Id
- BG005
- value
- 108
- group Id
- BG006
- value
- 259
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- title
- No
- param Type
- NUMBER
- title
- Prior Anti-Myeloma Therapies
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 76
- group Id
- BG005
- value
- 72
- group Id
- BG006
- value
- 178
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 37
- group Id
- BG005
- value
- 36
- group Id
- BG006
- value
- 81
- title
- No
- param Type
- NUMBER
- title
- Prior Thalidomide Exposure
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 84
- group Id
- BG005
- value
- 82
- group Id
- BG006
- value
- 191
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 29
- group Id
- BG005
- value
- 26
- group Id
- BG006
- value
- 68
- title
- No
- param Type
- NUMBER
- title
- Prior Stem Cell Transplant
- unit Of Measure
- participants
- population Description
- Intent to treat population from both phases
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle